 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Cephalon, Inc.
 |
Cephalon, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Dane Lundbeckmulls selling Cephalon stake Aug 17 2001 02:54 AM PDT
Cephalon loss narrows on sales of sleep disorder drug Aug 07 2001 04:47 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Cephalon just wants a chance to get "a head" by helping others stay awake. The company (whose name comes from the Greek for "head") sells Provigil, a treatment for the sleep disorder narcolepsy licensed from Laboratoire L. Lafon. It markets the drug in Australia, Ireland, the UK, and the US. The company is trying to extend the drug's use for other sleep-related conditions, cancer, and Alzheimer's disease. Cephalon's drug development activities focus on neurodegenerative diseases, including Parkinson's disease and ALS (also known as Lou Gehrig's disease), as well as cancer and sleep disorders. The firm also sells epilepsy treatment Gabitril and cancer pain medication Actiq.
COMPETITION |
 |
Amgen Inc. (AMGN)
DRAXIS Health Inc. (DRAX)
Sanofi-Synthélabo (SAN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 111.80
1-Yr. Sales Growth: 149.0%
Employees: 513
Revenue per employee: $217,933.72
KEY PEOPLE |
 |
Frank Baldino
CEO
J. Kevin Buchi
CFO
CONTACT INFO |
 |
145 Brandywine Pkwy.
West Chester, PA 19380
US
Phone: 610-344-0200
Fax: 610-344-0065
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |